Health Canada
www.hc-sc.gc.ca
Common menu bar links
Drugs and Health Products
For Health Professionals - 2009
December
- Cerezyme (imiglucerase for injection) - Supply and Recommendations for Restarting Cerezyme - Genzyme Canada Inc.
- For Health Professionals [2009-12-29]
- For the Public [2009-12-29]
- Myfortic (mycophenolate sodium) - Reports of Pure Red Cell Aplasia in Patients - Novartis Pharmaceuticals Canada Inc.
- For Health Professionals [2009-12-23]
- For the Public [2009-12-23]
- Thyrogen (thyrotropin alfa for injection): Caution with Preparation and Administration - Genzyme
- For Health Professionals [2009-12-09]
- Cerezyme (imiglucerase for injection), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa) and Aldurazyme (laronidase): Caution with Preparation and Administration - Genzyme
- For Health Professionals [2009-12-09]
- Exjade (deferasirox) - Proposed Changes to the Canadian Product Monograph - Novartis Pharmaceuticals Canada Inc.
- For Health Professionals [2009-12-03]
- For the Public [2009-12-03]
- Rapamune (sirolimus) - Blood Level Measurement Changes
- For Health Professionals [2009-12-02]
- For the Public [2009-12-02]
November
- Heparin - Decreased Potency as a Result of New United States Pharmacopeia (USP) Standards
- Notice to Hospitals [2009-11-26]
- Important Information on Changes to Heparin Potency [2009-11-26]
- Foreign Particles Found In Certain Products From Genzyme [2009-11-25]
- Authorization for Sale and Post-Market Activities for Arepanrix H1N1 Vaccine - GlaxoSmithKline Inc.
- For Health Professionals [2009-11-16]
- Association of Relenza (zanamivir) dry powder for inhalation with fatal outcome when administered by nebulization instead of inhalation - GlaxoSmithKline
- For Health Professionals [2009-11-05]
October
- Type I Product Recall of Propofol Injection, 1 g/100 mL and 500 mg/50 mL Due to the Presence of Particulate Matter - Hospira Healthcare Corporation
- For Health Professionals
- For Health Professionals [2009-10-30]
- Type II Product Recall of Apo-Lithium Carbonate SR 300 mg strength tablets - Apotex Inc.
- For Health Professionals [2009-10-28]
- Potential Risk of Serious Adverse Health Consequences with Inadvertent Administration of Cesamet (nabilone) Capsules 1 mg Instead of Trazorel (trazodone hydrochloride) Tablets 50 mg Due to Mislabelling - Valeant Canada Limited
- For Health Professionals [2009-10-26]
- Important Tamiflu Information for Health Professionals [2009-10-23]
- Association of Rituxan (rituximab) with Progressive Multifocal Leukoencephalopathy (PML) - Hoffmann-La Roche Limited
- For Health Professionals [2009-10-23]
- For the Public [2009-10-23]
- Health Canada issued important safey information on CEFTRIAXONE
- Notice to Hospitals [2009-10-20]
-
Risk of Entrapment of Patients in Hospital Beds
- Notice to Hospitals [2009-10-20]
-
New Safety Information Regarding Intelence (etravirine) and Severe Skin and Hypersensitivity Reactions - Tibotec, a division of Janssen-Ortho Inc.
- For Health Professionals [2009-10-19]
- Important Information About the Risk of Dosing Error for Tamiflu (oseltamivir phosphate) Powder for Oral Suspension (12 mg/mL) - Hoffmann-La Roche Limited
- For Health Professionals [2009-10-15]
- Recall Notice, Portex Uncuffed Pediatric-Sized Tracheal Tubes - Smiths Medical Canada Limited- For Health Professionals [2009-10-13]
- Important Safety Information Regarding the Use of Sleep Aid Drugs and the Risk of Complex Sleep-Related Behaviours [2009-10-07]
September
- Important Safety Information on Hospira Devices that have Defective AC Power Cords - Hospira Healthcare Corporation
- For Health Professionals [2009-10-01]
- Notice to Hospitals [2009-09-22]
August
- Safety Update on TNF Blockers and Risk of Cancer in Children and Young Adults [2009-08-20]
- Potential interaction of Proton Pump Inhibitors (PPIs) with Plavix (clopidogrel) - sanofi-aventis Canada Inc. and Bristol-Myers Squibb Canada Co.
- For Health Professionals [2009-08-20]
- For the Public [2009-08-20]
- Health Canada Reviewing Possible Association of Asthma Drug Xolair (Omalizumab) with Increased Risk of Cardiovascular Problems [2009-08-13]
- Important Safety Information on Medtronic Paradigm Quick-set Infusion Sets (Models MMT-396, MMT-397, MMT-398 and MMT-399)
- Notice to Hospitals [2009-08-06]
- Public Advisory [2009-08-06]
- Oral sodium phosphate products are no longer authorized for purgative use - Pharmascience Inc. and Odan Laboratories Ltd.
- For Health Professionals [2009-08-05]
- Health Canada Information Update [2009-08-05]
July
- Association of Telzir (fosamprenavir) with a potential increased risk of myocardial infarction (heart attack) - GlaxoSmithKline Inc.
- For Health Professionals [2009-07-22]
- For the Public [2009-07-22]
- Hardcore Energize Bullet Liquid Energy Drink Subject To Tampering [2009-07-06]
June
- Updated Labelling for Piroxicam - Drug No Longer to be Used for Acute Pain or Inflammation [2009-06-25]
- Market withdrawal of Raptiva (efalizumab) in Canada - EMD Serono Canada Inc.
- For Health Professionals [2009-06-17]
- For the Public [2009-06-17]
- Important Safety Information concerning Kappa 600/700/900 Series and Sigma 100/200/300 Series Implantable Pulse Generators - Medtronic of Canada Ltd.
- For Health Professionals [2009-06-05]
- Information on the association of CellCept (mycophenolate mofetil) with a potential risk of pure red cell aplasia (PRCA) - Hoffmann-La Roche Limited
- For Health Professionals [2009-06-04]
- For the Public [2009-06-04]
May
- Recall of one lot of Dobutamine Hydrochloride Injection 250 mg /20 mL due to labelling error regarding dose - Teva Novopharm
- Notice to Hospitals [2009-05-21]
- Recall of one lot of Rofact (rifampin) 300 mg due to labelling error - Valeant Canada Limited
- For Health Professionals [2009-05-21]
- Important Safety Information - BHM/Medi-Man Combi Sling - Possible Stitching Failure - BHM Medical Inc.
- Notice to Hospitals [2009-05-14]
- Association of TARCEVA (erlotinib) with cases of gastrointestinal perforation, Stevens-Johnson syndrome, and corneal perforation - Hoffmann-La Roche Limited
- For Health Professionals [2009-05-11]
- For the Public [2009-05-11]
- Important Safety Information Concerning Pre-filled Saline and Heparin Syringes Manufactured by MedXL Inc.
- Notice to Hospitals [2009-05-06]
April
- Association of Herceptin (trastuzumab) with Oligohydramnios - Hoffman-La Roche Limited
- For Health Professionals [2009-04-24]
- For the Public [2009-04-24]
- Association of Enbrel (etanercept) with Histoplasmosis and Other Invasive Fungal Infections - Amgen Canada Inc.
- For Health Professionals [2009-04-23]
- For the Public [2009-04-23]
- Urgent Device Correction Letter: COLLEAGUE Single Channel and Triple Channel Volumetric Infusion Pumps - Baxter Corporation Canada
- For Health Professionals [2009-04-03]
- Standards for Improved Fire Safety of Mattresses
- Notice to Hospitals [2009-04-02]
March
- Association of Phosphocol P32 (Chromic Phosphate P32) with acute lymphocytic leukemia (ALL) - Tyco Healthcare
- For Health Professionals [2009-03-30]
- For the Public [2009-03-30]
- Urgent Medical Device Correction - AED Plus Defibrillator: serial numbers below x - - -200000 - ZOLL Medical Corporation
- For Health Professionals [2009-03-26]
- Misuse of blood lancing devices
- Notice to Hospitals [2009-03-24]
- Drug Release Information for the EVRA Transdermal Contraceptive System - Janssen-Ortho Inc.
- For Health Professionals [2009-03-19]
- For the Public [2009-03-19]
- Safety information regarding topical anesthetics and serious adverse events - AstraZeneca Canada Inc. and Smith & Nephew Inc.
- For Health Professionals [2009-03-05]
- For the Public [2009-03-05]
February
- Suspension of marketing of Raptiva (efalizumab) in Canada - EMD Serono Canada Inc.
- For Health Professionals [2009-02-20]
- For the Public [2009-02-20]
- New Safety Information Regarding Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (natalizumab) - Biogen Idec Canada Inc.
- For Health Professionals [2009-02-18]
- For the Public [2009-02-18]
January
- Additional safety information related to Botox / Botox Cosmetic (botulinum toxin type A) - Allergan Canada
- For Health Professionals [2009-01-13]
- Health Canada Information Update [2009-01-13]
- Health Canada Endorsed Important Safety Information on Dobutamine Hydrochloride Injection 250 mg/20 ml - Teva novopharm
- Notice to Hospitals [2009-01-12]
- Important Changes to the Dose Conversion Guidelines for Fentanyl Transdermal Systems - Janssen-Ortho Inc., Cobalt Pharmaceuticals Inc., Novopharm Limited, Ranbaxy Pharmaceuticals Canada Inc. and ratiopharm inc.
- For Health Professionals [2009-01-07]
- For the Public [2009-01-07]
- Notice to Hospitals [2009-01-07]
- Recall of Lot 7101490 of PPC Piperacillin/Tazobactam for Injection, 4.5g/vial - Pharmaceutical Partners of Canada Inc.
- For Health Professionals [2009-01-05]
